Accepted at 2:16 p.m. Dec, 22, 2024 by Eli.Tanenbaum
Author: mohannadkh10
Related Note: 1477089786478
Rationale for change

Selective norepinephrine reuptake inhibitors Is what Amboss and Uworld use to describe the MOA

not sure why NET, also Amboss use the abbr NRI


Source: AMBOSS - https://next.amboss.com/us/article/rP0fTT?q=atomoxetine#Z7a55ca00b3417cd202511d0599da8973

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#NBME::26 #AK_Step2_v12::#AMBOSS::uJ0pDS #AK_Step2_v12::#UWorld::COMLEX::102812 #AK_Step1_v12::#NBME::31 #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#UWorld::COMLEX::26211 #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::06_Antidepressants::*Preferred_Medications_For_Selected_Psychiatric_Conditions #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry #AK_Step2_v12::#SketchyPsych::07_Child_&_Adolescent_Psychiatry::02_ADHD::01_ADHD #AK_Step1_v12::#Bootcamp::Psychiatry::02_Developmental_Disorders::01_ADHD #AK_Step3_v12::#UWorld::10035 #AK_Step1_v12::#AMBOSS::dLao9O #AK_Step2_v12::#AMBOSS #AK_Step2_v12::#AMBOSS::cHaa6N #AK_Step1_v12::#AMBOSS::QA0uji #AK_Step1_v12::#B&B::19_Psych::02_Pathology::03_ADHD_and_Autism #AK_Step2_v12::#B&B::12_Pediatrics::03_Other::03_Child_Psychiatry #AK_Step2_v12::#UWorld::Step::15121 #AK_Step1_v12::#UWorld::Step::15282 #AK_Step1_v12::#SketchyPharm::01_Autonomic_Drugs::02_Sympathetic::02_Indirect_Sympathomimetics #AK_Step1_v12::#FirstAid::13_Psych::02_Pathology::03_Childhood_and_early-onset_disorders::01_Attention-deficit_hyperactivity_disorder #AK_Step1_v12::#FirstAid::05_Pharm::02_Autonomic_Drugs::11_Sympathomimetics::*Indirect::Atomoxetine